Loading clinical trials...
Loading clinical trials...
A Randomized, Single-Blind, Dose-Rising, Placebo-Controlled, Crossover Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus
This study will be the first evaluation of exenatide in adolescent subjects with type 2 diabetes mellitus and is designed to evaluate the blood levels of the drug (pharmacokinetics), the drug's biochemical and physiological effects (pharmacodynamics), and tolerability of exenatide in these subjects.
Age
10 - 16 years
Sex
ALL
Healthy Volunteers
No
Research Site
Little Rock, Arkansas, United States
Research Site
San Diego, California, United States
Research Site
Denver, Colorado, United States
Research Site
Louisville, Kentucky, United States
Research Site
San Antonio, Texas, United States
Start Date
February 1, 2006
Primary Completion Date
February 1, 2007
Completion Date
February 1, 2007
Last Updated
February 23, 2015
13
ACTUAL participants
Exenatide - Exenatide - Placebo
DRUG
Exenatide - Placebo - Exenatide
DRUG
Placebo - Exenatide - Exenatide
DRUG
Lead Sponsor
AstraZeneca
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07433062